▲ 541 ▼ New Vaccine Can Completely Reverse Autoimmune Diseases Like Multiple Sclerosis, Type 1 Diabetes, and Crohn’s Disease (scitechdaily.com) submitted 2 years ago by m3t00@lemmy.world [M] to c/science@lemmy.world 101 comments fedilink hide all child comments In trials
[–] SCB@lemmy.world 1 point 2 years ago (2 children) It’s not active suppression most of the time, This is your initial claim, though. permalink fedilink source parent hideshow 4 child comments replies: [–] sigmaklimgrindset@sopuli.xyz 2 points 2 years ago Also, apologies if I come off as aggressive at any point, I still have a lot of residual anger over what I experienced with my former career. permalink fedilink source parent [–] sigmaklimgrindset@sopuli.xyz 1 point 2 years ago No, my initial claim was: Curing diabetes isn’t as profitable as selling insulin. That’s why it doesn’t get funded. Then you opined that whoever comes up with a cure wins, which should be true in a perfect world. In fact, most researchers would agree with you. Unfortunately, a lot of MBA’s in these pharma companies don’t see it that way, and my reply to you was trying to outline the realities of that. I focussed more on the patent-and-bury part because this is the one method less known to the public (and less used), but underfunding research that can do a public good but isn’t profitable is a common technique by corporations in research, regardless of the discipline. My bad, I thought this was common knowledge, but it probably isn’t for people who aren’t in PhD/post-doc research roles. permalink fedilink source parent
[–] sigmaklimgrindset@sopuli.xyz 2 points 2 years ago Also, apologies if I come off as aggressive at any point, I still have a lot of residual anger over what I experienced with my former career. permalink fedilink source parent
[–] sigmaklimgrindset@sopuli.xyz 1 point 2 years ago No, my initial claim was: Curing diabetes isn’t as profitable as selling insulin. That’s why it doesn’t get funded. Then you opined that whoever comes up with a cure wins, which should be true in a perfect world. In fact, most researchers would agree with you. Unfortunately, a lot of MBA’s in these pharma companies don’t see it that way, and my reply to you was trying to outline the realities of that. I focussed more on the patent-and-bury part because this is the one method less known to the public (and less used), but underfunding research that can do a public good but isn’t profitable is a common technique by corporations in research, regardless of the discipline. My bad, I thought this was common knowledge, but it probably isn’t for people who aren’t in PhD/post-doc research roles. permalink fedilink source parent